Compare CLAR & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLAR | ANIX |
|---|---|---|
| Founded | 1957 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.9M | 88.8M |
| IPO Year | 1998 | 2013 |
| Metric | CLAR | ANIX |
|---|---|---|
| Price | $3.06 | $2.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $4.08 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 279.8K | 99.1K |
| Earning Date | 05-07-2026 | 05-27-2026 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | 11.68 | ★ 12.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $228,000.00 | $210,000.00 |
| Revenue This Year | $5.27 | N/A |
| Revenue Next Year | $3.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.53 | $2.44 |
| 52 Week High | $4.03 | $5.46 |
| Indicator | CLAR | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 57.32 | 41.38 |
| Support Level | $2.59 | $2.65 |
| Resistance Level | $3.08 | $3.12 |
| Average True Range (ATR) | 0.15 | 0.12 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 86.18 | 21.48 |
Clarus Corp is a designer, developer, manufacturer, and distributor of outdoor equipment and lifestyle products focused on the climb, ski, mountain, sport, and skincare markets. The company operates through the Outdoor segment, which includes Black Diamond Equipment and PIEPS, is a world-wide leader in designing, manufacturing, and marketing outdoor engineered equipment and apparel for climbing, mountaineering, trail running, backpacking, skiing, and a wide range of other year-round outdoor recreation activities. The Adventure segment, which includes Rhino-Rack, MAXTRAX and TRED, is a manufacturer of engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, recovery boards and accessories in Australia and New Zealand and U.S.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.